CD4 and leukemia: A further advantageous feature of the DN4.99 TCR is its derivation from a CD4/CD8 double negative T cell clone, which enables its coreceptor-independent CD1c recognition and allows it to be used to efficiently redirect both CD8+ and CD4+ transduced T cells against CD1c+ leukemia targets.